Literature DB >> 1612333

Serum levels of cytokines in chronic liver diseases.

H Tilg1, A Wilmer, W Vogel, M Herold, B Nölchen, G Judmaier, C Huber.   

Abstract

Serum levels of interleukin-1 (IL-1 beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma), and C-reactive protein (CRP) were investigated in patients with chronic liver diseases (CLD) and correlated with the type of underlying disease and various clinical and laboratory parameters. Two hundred sixty-four patients suffering from various CLD were studied; 136 cases presented with liver cirrhosis, and 128 patients were in the noncirrhotic stage of their underlying liver diseases. Serum levels of IL-1 beta, IL-6, TNF-alpha, IFN-gamma, and CRP were elevated in patients with CLD. Endogenous cytokine patterns in CLD were stage dependent and only marginally affected by the type of underlying disease. The cirrhotic group of CLD patients showed higher serum levels in IL-1 beta, IL-6, TNF-alpha, and CRP than did noncirrhotic cases, and these differences reached the level of statistical significance. IL-1 beta and TNF-alpha values were closely correlated but did not correlate with IL-6 levels. Elevated concentrations of cytokines represent a characteristic feature of CLD regardless of underlying disease. This and the apparent stage-dependency suggest that enhanced endogenous cytokine levels represent a consequence of liver dysfunction rather than of inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1612333     DOI: 10.1016/0016-5085(92)91122-k

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  171 in total

1.  Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility.

Authors:  R Wiest; S Das; G Cadelina; G Garcia-Tsao; S Milstien; R J Groszmann
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease.

Authors:  Othmar Ludwiczek; Arthur Kaser; Daniela Novick; Charles A Dinarello; Menachem Rubinstein; Wolfgang Vogel; Herbert Tilg
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

3.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.

Authors:  Christopher Johnson; Yuyan Han; Nathan Hughart; Jennifer McCarra; Gianfranco Alpini; Fanyin Meng
Journal:  Transl Gastrointest Cancer       Date:  2012-04-01

Review 4.  Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis.

Authors:  Ming Luo; Jian-Yang Guo; Wu-Kui Cao
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

5.  1, 25(OH)₂D₃ inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes.

Authors:  Jian Guo; Zhenhua Ma; Qingyong Ma; Zheng Wu; Ping Fan; Xiaojie Zhou; Lulu Chen; Shuang Zhou; David Goltzman; Dengshun Miao; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

6.  Sophocarpine attenuates liver fibrosis by inhibiting the TLR4 signaling pathway in rats.

Authors:  Hui Qian; Jian Shi; Ting-Ting Fan; Jiao Lv; Si-Wen Chen; Chun-Yan Song; Zhi-Wu Zheng; Wei-Fen Xie; Yue-Xiang Chen
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

7.  No additive effect between Helicobacter pylori infection and portal hypertensive gastropathy on inducible nitric oxide synthase expression in gastric mucosa of cirrhotic patients.

Authors:  Usama A Arafa; Yasuhiro Fujiwara; Kazuhide Higuchi; Masatsugu Shiba; Toshiyuki Uchida; Toshio Watanabe; Kazunari Tominaga; Nobuhide Oshitani; Takayuki Matsumoto; Tetsuo Arakawa
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

Review 8.  Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.

Authors:  Mahmoud Fathy Dondeti; Eman Anwar El-Maadawy; Roba Mohamed Talaat
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

9.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

10.  Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.

Authors:  Curtis Cooper; Stephan Shafran; Susan Greenbloom; Robert Enns; John Farley; Nir Hilzenrat; Kurt Williams; Magdy Elkashab; Nabil Abadir; Manuela Neuman
Journal:  Can J Gastroenterol Hepatol       Date:  2013-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.